NCT00410956View on ClinicalTrials.gov

Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 9, 2007

Primary Completion Date

May 7, 2024

Study Completion Date

May 7, 2024

Conditions

Liver Cancer

Interventions

BIOLOGICAL

bevacizumab

DRUG

dexamethasone

DRUG

floxuridine

GENETIC

protein expression analysis

OTHER

flow cytometry

OTHER

immunoenzyme technique

OTHER

immunohistochemistry staining method

OTHER

immunologic technique

OTHER

laboratory biomarker analysis

PROCEDURE

dynamic contrast-enhanced magnetic resonance imaging

Trial Locations (2)

10021

New York Weill Cornell Cancer Center at Cornell University, New York

10065

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00410956 - Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery | Biotech Hunter | Biotech Hunter